Cognition
Cortagen is a research-use product carried by vendors we track, grouped under Cognition. For research use only; an editorial review is pending.
Cortagen is offered by one or more vendors we track. We have not yet written a detailed editorial summary for this compound. The offerings below reflect what vendors currently carry. For research use only — verify dosing, handling, and safety against primary sources.
Where to buy
Some links on this page are affiliate links. We may earn a commission when you purchase through them, at no extra cost to you.
Best $/mg
Evidence level
Preclinical only
A short synthetic peptide (Ala-Glu-Asp-Pro) developed in Russia in the Khavinson bioregulator program, marketed for vascular and connective tissue support. Almost all published literature is from a single Russian research group; independent replication is essentially absent.
Mechanism
Mechanism not yet documented.
Researched benefits
Claimed vascular wall support
Russian-language literature reports modulation of endothelial gene expression and improved microvascular parameters in elderly cohorts. Sample sizes are small and methodologies are typically not blinded to Western trial standards.
Connective tissue / aging context
Positioned within the Khavinson 'cytomax/cytogen' framework as a peptide bioregulator targeting vascular wall and connective tissue tissue programs. The conceptual framework is not widely accepted outside the originating group.
Short tetrapeptide kinetics
Small molecular size suggests rapid systemic distribution. No formal PK studies in peer-reviewed Western literature.
Risks & cautions
Very limited safety data
No regulatory review outside Russia. Safety inferences rest on the originating research group's reports. Independent toxicology data is essentially absent.
No high-quality efficacy data
Effectively all positive data comes from a single research lineage. No randomized, blinded, placebo-controlled Western trials have been published. Treat efficacy claims as unverified.
Injection-site reactions
Standard parenteral risks: local erythema, bruising. No unique signal beyond what is expected for any subcutaneous peptide.
Unknown drug interactions
Mechanism is poorly characterized, so interactions cannot be predicted. Caution with anticoagulants given the vascular wall framing.
Dosing
Commonly reported: 1–2 mg subcutaneously daily for 10–20 days, sometimes repeated quarterly. Doses derive from Russian protocols rather than controlled trials.
Vial sizes
--
Half-life
--
Route
--
Reconstitute with bacteriostatic water. Khavinson protocols typically describe cycled short courses (10–20 days) rather than continuous dosing. Oral capsule formulations are also sold but bioavailability of intact tetrapeptide via the gut is questionable.
Contraindications
In depth
Cortagen is one of a large family of "short peptide bioregulators" developed since the 1970s at the Saint Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson. The program isolated peptide fractions from animal tissues (the original "cytomax" preparations) and later synthesized short defined-sequence peptides ("cytogens") proposed to recapitulate tissue-specific signaling.
Cortagen is reportedly tetrapeptide Ala-Glu-Asp-Pro, positioned as a synthetic analog of a vascular wall / connective tissue peptide fraction. It sits in the same conceptual family as Cortexin, Epitalon (epithalon), Thymalin, Thymogen, Pinealon, and others.
Important framing: essentially the entire scientific literature on Khavinson bioregulators originates from a single research network. Independent Western replication is sparse to nonexistent. This does not prove the peptides are inert, but it means standard pharmacological evidence — blinded RCTs, mechanism-of-action papers from independent groups, regulatory dossiers — is missing.
Proposed mechanism within the Khavinson framework: short peptides penetrate cells (and possibly nuclei), bind to DNA/chromatin, and modulate transcription of tissue-specific gene programs. For Cortagen the proposed target tissue is vascular wall and connective tissue.
The proposed mechanism has not been confirmed in independent biochemistry. The molecular targets, receptors, or DNA-binding evidence published outside the originating group are essentially absent.
Russian-language reports describe improved microvascular and connective tissue parameters in older cohorts. Trial designs typically use small samples, open-label or single-blind methodology, and surrogate endpoints (rheologic indices, capillaroscopy findings) rather than hard clinical outcomes. None of this has been replicated in Western randomized trials.
Within the Khavinson program, rodent studies report modulation of vascular wall histology and connective tissue parameters. Outside that program, dedicated cortagen animal pharmacology is essentially absent from the indexed literature.
In Russian practice cortagen is often included in multi-peptide bioregulator protocols alongside Cortexin (cerebral), Thymalin (immune), Epitalon (pineal), and others. There is no controlled evidence that these stacks produce additive or synergistic effects — the protocols are clinical convention rather than data-driven.
In Western research-peptide practice, cortagen is uncommon. It is sometimes added to vascular/anti-aging stacks alongside BPC-157, TB-500, or GHK-Cu, but no formal interaction data exists.
References
